3.Comprehensive understanding of bronchiolitis in children.
Chinese Journal of Pediatrics 2012;50(10):722-725
Bronchiolitis
;
epidemiology
;
pathology
;
therapy
;
Bronchiolitis Obliterans
;
epidemiology
;
pathology
;
therapy
;
Child
;
Haemophilus Infections
;
epidemiology
;
pathology
;
therapy
;
Humans
4.Bronchitis obliterans in children: report of two cases and literature review.
Jing WANG ; Yan YANG ; Shun-ying ZHAO
Chinese Journal of Pediatrics 2010;48(10):764-766
OBJECTIVEBronchitis obliterans is a severe and extremely rare complication of respiratory tract infections in children and is characterized by massive atelectasis and collapse of the affected lung.
METHODThe clinical manifestations, characteristic imaging of two cases with bronchitis obliterans were summarized.
RESULTThese two cases complained of cough and episodes of wheezing with exercise. Chest auscultation revealed bronchial breath sounds on the right side. High-resolution computed tomography (HRCT) scan showed atelectasis of the right lung and dilated central airways. Mycoplasma complement fixation antibody (CF-Ab) titer was 1:320. The diagnosis of bronchitis obliterans was made according to the current diagnostic criteria. They were treated with low-dose erythromycin [5 mg/(kg × d)], ultrasonically nebulized Pulmicort inhalation, and regular bronchoscopic lavage. Follow-up of the two cases showed that case one had a partial lung re-expansion after six months, but case two had no significant improvement.
CONCLUSIONIn the process of diagnosis of atelectasis, bronchitis obliterans should be noticed. A conservative treatment is effective in certain cases, but pneumonectomy or lobectomy should only be considered as the last option.
Bronchiolitis Obliterans ; diagnosis ; therapy ; Child, Preschool ; Female ; Humans ; Male ; Pulmonary Atelectasis ; diagnosis ; therapy
5.A Case of Bronchiolitis Obliterans Organizing Pneumonia Following CHOP Chemotherapy and Filgrastim Use in a Patient with Diffuse Large B-cell Lymphoma.
Wou Young CHUNG ; Min Kwang BYUN ; Jin Hyoung LEE ; Chang Hoon HAHN ; Shin Myung KANG ; Jin Seok KIM ; San Ho CHO ; Young Sam KIM ; Se Kyu KIM ; Joon CHANG ; Sung Kyu KIM ; Moo Suk PARK
Tuberculosis and Respiratory Diseases 2005;59(5):561-565
Bronchiolitis obliterans organizing pneumonia (BOOP) is often diagnosed in patients with pneumonia who respond poorly to antibiotics. BOOP is often idiopathic, and the etiology of the remaining cases has been attributed to a wide range of agents or medical conditions. When a patient develops the clinical symptoms characteristic of BOOP, the medical team must endeavor to determine the etiology of this disease because it can be treated with glucocorticoid and avoidance of the causative agent. In particular, if BOOP is diagnosed during or after chemotherapy for a malignancy, the possible culprit agent can be the anti cancer drugs but other drugs used for supportive care must be also be considered. We report a case of BOOP that arose after CHOP chemotherapy and a filgrastim injection in a patient with a diffuse large B-cell lymphoma.
Anti-Bacterial Agents
;
B-Lymphocytes*
;
Bronchiolitis Obliterans*
;
Bronchiolitis*
;
Cryptogenic Organizing Pneumonia*
;
Drug Therapy*
;
Humans
;
Lymphoma, B-Cell*
;
Pneumonia
;
Filgrastim
6.Clinical characteristics of bronchiolitis obliterans in pediatric patients.
De-hui CHEN ; Yu-neng LIN ; Shu-ling LAN ; Xiao-an PAN ; Qing-si ZENG ; Zhen-tao HE ; Ming LIANG ; Bi-yun ZHANG ; Shang-zhi WU ; Jia-xing XU ; Xiao-yan GONG ; Nan-shan ZHONG
Chinese Journal of Pediatrics 2012;50(2):98-102
OBJECTIVETo analyze the clinical characteristics, image findings, laboratory examination, the therapeutic methods and clinical outcomes of bronchiolitis obliterans (BO) in pediatric patients.
METHODTwenty-six pediatric patients with BO were reported. All data were collected from cases who were hospitalized in the Department of Pediatrics, First Affiliated Hospital of Guangzhou Medical College from June 1(st), 2009 to the April 30(th), 2011, and infectious agents, clinical manifestations, risk factors, changes in imageology, laboratory examination, therapeutic methods and treatment responses were analyzed.
RESULTThe ranges of age at onset was 4.5 months-8 years in 26 cases (18 boys and 8 girls). The course of disease was (6.2 ± 3.5) months. The period of followed-up ranged from 2 to 24 months. The common clinical characteristics were persistent wheezing of different severity (26 cases, 100%), cough (24 cases, 92%), intolerance to exercise (22 cases, 85%), short of breath (21 cases, 81%), retraction (20 cases, 77%), wheezy phlegm (16 cases, 62%), keeping with crackles (10 cases, 38%), cyanosis around the mouth (3 cases, 12%) and no clubbed fingers (toes). In 18 cases the etiology was detected, mycoplasma (11 cases, 42%), respiratory syncytial virus (4 cases, 15%), parainfluenza virus (2 cases, 8%), influenza virus A (2 cases, 8%) and influenza virus B (2 cases, 8%), human bocavirus (HBoV) (1 case, 4%). There were 8 cases (31%) with combined infection. Chest X-ray in 10 cases indicated changes suggestive of bronchopneumonia (38%), in only 1 case there was an image of interstitial pneumonia disease (4%). All the patients were diagnosed by high-resolution computerized tomography (HRCT). All cases were demonstrated to have air retention, poor blood perfusion in lung, just like "Westemark sign" with HRCT. In 19 cases antineutrophil cytoplasmic antibody (ANCA) was determined and 10 patients (53%) were positive for P-ANCA, and 8 cases (42%) were positive for C-ANCA. All patients received oral corticosteroid and low doses azithromycin. In 13 cases (50%) the treatment effectively reduced the severity of disease and the frequency of cough and wheezing. The average number of days for symptom improvement was (7.1 ± 4.8) days.
CONCLUSIONRespiratory infection plays an important role in BO in children. The chronic and persistent wheezing, cough, intolerance to exercises, short breath, retraction were the main clinical manifestations. But these symptoms are non-specific. Chest X-ray can not provide enough information for diagnosis. Classical "Westemark sign" with HRCT is an important sign. ANCA with a high positive rate (approximately 50%) suppose immuno-lesion in BO. Oral corticosteroid and methotrexate may relieve clinical symptoms.
Bronchiolitis Obliterans ; diagnosis ; etiology ; therapy ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Male ; Prognosis ; Treatment Outcome
7.A Case of the Bleomycin-Induced Bronchiolitis Obliterans Organizing Pneumonia.
Chang Hoon HAHN ; Jin Wook MOON ; Jae Hyun CHANG ; Byoung Wook CHOI ; Dong Whan SHIN ; Se Kyu KIM ; Joon CHANG ; Sung Kyu KIM ; Young Sam KIM
Tuberculosis and Respiratory Diseases 2003;55(3):311-316
A 34-year-old man was admitted to our hospital due to fever and cough. He received the combination anti-cancer chemotherapy for testicular tumor, including bleomycin. The chest X-ray showed consolidation and ground glass opacity on the right upper lobe and subpleural areas of other lobes. This condition was initially misdiagnosed as a pneumonia, but consolidation did not disappear after antibiotics treatment. We performed transbronchial lung biopsy and bleomycin induced pulmonary toxicity was confirmed. The bleomycin induced lung injury is the most common chemotherapeutically induced pulmonary disease. Bleomycin induced Bronchiolitis Obliterans Organizing Pneumonia(BOOP) is less common than interstitial pneumonitis and respond well to corticosteroid treatment.
Adult
;
Anti-Bacterial Agents
;
Biopsy
;
Bleomycin
;
Bronchiolitis Obliterans*
;
Bronchiolitis*
;
Cough
;
Cryptogenic Organizing Pneumonia*
;
Drug Therapy
;
Fever
;
Glass
;
Humans
;
Lung
;
Lung Diseases
;
Lung Diseases, Interstitial
;
Lung Injury
;
Pneumonia
;
Thorax
8.A Case of Organizing Pneumonia Associated with FOLFIRI Chemotherapy.
Yoon Jeong LEE ; Jun Hyun KIM ; Sun Woong KIM ; Won Chan KANG ; Soo Jung KIM ; Ji Hye KIM ; Sun Jong KIM
Tuberculosis and Respiratory Diseases 2014;77(6):262-265
The combination chemotherapy of irinotecan with 5-fluorouracil and leucovorin (FOLFIRI regimen) was recently proven to be beneficial in patients with advanced colorectal cancer. Pulmonary toxicity is very rare in adverse effects of irinotecan. No case of organizing pneumonia (also known as bronchiolitis obliterans organizing pneumonia) associated with FOLFIRI chemotherapy has been reported. We experienced a case of a 62-year-old man who presented persistent dry cough and progressive dyspnea after receiving chemotherapy with FOLFIRI regimen. After surgical lung biopsy, the patient was diagnosed with FOLFIRI chemotherapy-induced organizing pneumonia which was successfully treated with steroid therapy.
Biopsy
;
Bronchiolitis Obliterans
;
Colorectal Neoplasms
;
Cough
;
Cryptogenic Organizing Pneumonia
;
Drug Therapy*
;
Drug Therapy, Combination
;
Dyspnea
;
Fluorouracil
;
Humans
;
Leucovorin
;
Lung
;
Middle Aged
;
Pneumonia*
9.A case of interstitial lung diseasec caused by Rituximab in non-Hodgkin lymphoma.
Young Jun CHOI ; Woo Jin JUNG ; Se Il OH ; Min Hoyk JEON ; Hee Jung SOHN ; Eun Mee HAN ; Cheolwon SUH
Korean Journal of Medicine 2006;71(4):449-455
Rituximab targets CD20+ B cells and has been used increasingly for the treatment of B-cell Non-Hodgkin Lymphoma, alone or in combination with cytotoxic agents. Rituximab can kill CD20+cells by multiple mechanisms. Rituximab therapy has often been associated with an infusion-related symptom complex consisting of fever, chills, and rigors that is usually self-limited. These complications are transient without long-term effects. Several delayed pulmonary events involving interstitial reactions and bronchiolitis obliterans with organizing pneumonia have recently been described in conjunction with the use of Rituximab. In the lymphoma patient presented here there was no respiratory symptoms; however, respiratory difficulty developed after the third round of Rituximab plus CHOP chemotherapy. High resolution computed tomography (HRCT) and positive emission tomography (PET) were performed and revealed diffuse ground glass opacities. We report a patient with Non-Hodgkin Lymphoma in whom interstitial lung disease developed after Rituximab therapy.
B-Lymphocytes
;
Bronchiolitis Obliterans
;
Chills
;
Cytotoxins
;
Drug Therapy
;
Fever
;
Glass
;
Humans
;
Lung Diseases, Interstitial
;
Lung*
;
Lymphoma
;
Lymphoma, Non-Hodgkin*
;
Pneumonia
;
Rituximab
10.Factors associated with long-term survival in critically ill patients following surgery for solid tumors complicated with paraneoplastic pemphigus.
Jia Xi PAN ; Sai Nan ZHU ; Shuang Ling LI ; Dong Xin WANG
Journal of Peking University(Health Sciences) 2022;54(5):981-990
OBJECTIVE:
Critically ill patients with solid tumors complicated with paraneoplastic pemphigus are usually treated in intensive care units (ICU) for perioperative management after surgical treatment. In this study, the clinical characteristics and predictors of long-term prognosis of these critically ill patients were analyzed.
METHODS:
the clinical and laboratory data of 63 patients with solid tumors complicated with paraneoplastic pemphigus admitted to ICU from 2005 to 2020 were retrospectively analyzed, and the survival status of the patients were followed up.
RESULTS:
Among the 63 patients, 79.4% had Castleman disease as the primary tumor, and 20.6% with other pathological types; 69.8% had severe-extensive skin lesions, and 30.2% had other skin lesions; the patients with bronchiolitis obliterans accounted for 44.4%, and 55.6% were not merged. Postoperative fungal infection occurred in 23.8% of the patients, and 76.2% without fungal infection. The median follow-up time was 95 months, and 25 patients died during the study period. The 1-year, 3-year and 5-year survival rates were 74.6% (95%CI 63.8%-85.4%), 67.4% (95%CI 55.6%-79.2%) and 55.1% (95%CI 47.9%-62.3%), respectively. The log-rank univariate analysis showed that the patients had age>40 years (P=0.042), preoperative weight loss>5 kg (P=0.002), preoperative albumin < 30 g/L (P < 0.001), paraneoplastic pemphigus complicated with bronchiolitis obliterans (P=0.002), and perioperative fungal infection (P < 0.001) had increased mortality. Cox univariate analysis showed that preoperative weight loss >5 kg (P=0.005), preoperative albumin < 30 g/L (P < 0.001), paraneoplastic pemphigus complicated with bronchiolitis obliterans (P=0.009), preoperative bacterial pulmonary infection (P=0.007), prolonged surgical time (P=0.048), postoperative oxygenation index (P=0.012) and low albumin (P=0.010) and hemoglobin concentration (P=0.035) in ICU, acute physiology and chronic health evaluation (APACHE Ⅱ) score (P=0.001); sequential organ failure assessment (SOFA) score (P=0.010), and postoperative fungal infection (P < 0.001) were risk factors for long-term survival. Cox regression model for multivariate analysis showed that preoperative weight loss > 5 kg (HR 4.44; 95%CI 1.47-13.38; P=0.008), and preoperative albumin < 30 g/L (HR 4.38; 95%CI 1.72-11.12; P=0.002), bronchiolitis obliterans (HR 2.69; 95%CI 1.12-6.50; P=0.027), and postoperative fungal infection (HR 4.85; 95%CI 2.01-11.72; P < 0.001) were independent risk factors for postoperative mortality.
CONCLUSION
The 5-year survival rate of critically ill patients undergoing surgery for paraneoplastic pemphigus combined with solid tumors is approximately 55.1%, with preoperative weight loss > 5 kg, albumin < 30 g/L, bronchiolitis obliterans and postoperative fungal infection were associated with an increased risk of near- and long-term postoperative mortality.
Adult
;
Albumins/therapeutic use*
;
Bronchiolitis Obliterans/pathology*
;
Critical Illness
;
Hemoglobins
;
Humans
;
Neoplasms/complications*
;
Paraneoplastic Syndromes/pathology*
;
Pemphigus/drug therapy*
;
Retrospective Studies
;
Weight Loss